Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06729593 · ClinicalTrials.gov registry record · Phase 3
Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
A Phase 3 study of Covid19, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 87
- Enrollment target
- 20
- Study locations
NCT06729593 is a Phase 3 study of Covid19 that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 87 participants, below the 2,701-participant average among 94 other Covid19 trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT06729593, a Phase 3 study of Covid19, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 87 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study looks at the safety and effectiveness of Remdesivir in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure. Participants in the study will be treated with Remdesivir plus current standard of care (SOC), or with placebo plus current SOC.
Conditions Studied
Interventions
- DRUG Corticosteroid
- BIOLOGICAL Remdesivir
- BIOLOGICAL Remdesivir Placebo
Study Locations (20)
California
- UCSF Fresno (Site 203-005), 155 N. Fresno Street - Fresno
- VA Loma Linda Healthcare System (Site 074-017), 11201 Benton Street - Loma Linda
- Cedars-Sinai Medical Center (Site 208-002), 8700 Beverly Boulevard - Los Angeles
- Ronald Reagan UCLA Medical Center (Site 203-002), 757 Westwood Plaza - Los Angeles
- UCSF Medical Center at Mount Zion (Site 203-007), 1600 Divisadero St. - San Francisco
- UCSF Medical Center (Site 203-001), Moffit-Long Hospital, 505 Parnassus Ave. - San Francisco
- Stanford University Hospital & Clinics (Site 203-003), 300 Pasteur Dr. - Stanford
New York
- Mount Sinai Medical Center (Site 301-012), Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place - New York
- Columbia University Irving Medical Center (Site 301-027), 177 Fort Washington Ave. - New York
- Montefiore Medical Center - Moses Hospital (Site 206-001), 111 E. 210th Street - The Bronx
- Montefiore Medical Center - Weiler campus (Site 206-003), 111 E. 210th Street - The Bronx
Colorado
- University of Colorado Hospital (Site 204-001), 12605 E. 16th Avenue - Aurora
- Denver Health Medical Center (Site 204-004), 780 Delaware Street, Pavilion B - Denver
District of Columbia
- MedStar Health Research Institute (Site 009-021), 110 Irving St., NW. - Washington D.C.
- Washington DC VA Medical Center (Site 009-004), 50 Irving Street, NW. - Washington D.C.
Massachusetts
- Massachusetts General Hospital (Site 202-002), 55 Fruit Street - Boston
- Baystate Medical Center (Site 201-001), Critical Care Research, 759 Chestnut Street - Springfield
Arizona
- Banner University Medical Center Tucson (Site 206-004), 1625 N. Campbell Avenue - Tucson
Georgia
- Emory University (Site 301-008), Bldg. A, Suite 2236, 1365 Clifton Rd., NE. - Atlanta
North Carolina
- Duke University Hospital (Site 301-006), 2301 Erwin Road - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2021-04-20 |
| Est. Completion | 2022-11-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06729593
The ClinicalTrials.gov registry entry for NCT06729593 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,701-participant average among 94 other Covid19 trials with a reported enrollment target (97% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Covid19 appearing as the primary indexed condition, and to 3 interventions - of which Corticosteroid is the first listed.
NCT06729593 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, New York, Colorado.
Frequently Asked Questions
What is clinical trial NCT06729593 about?
NCT06729593 is a clinical study titled "Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)". This study looks at the safety and effectiveness of Remdesivir in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure. Participants in the study will be treated with Remdesivir plus current standard of care (SOC), or with placebo plus curr...
What is the current status of trial NCT06729593?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 87 participants. The study started on 2021-04-20. Estimated completion is 2022-11-20.
What conditions does trial NCT06729593 study?
This clinical trial studies the following conditions: Covid19.
What interventions are being tested in trial NCT06729593?
The interventions under investigation include: Corticosteroid (DRUG), Remdesivir (BIOLOGICAL), Remdesivir Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT06729593?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06729593 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Covid19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
RECRUITING · Phase 3
-
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
COMPLETED · Phase 3
-
Aggrenox To Treat Acute Covid-19
COMPLETED · Phase 3
-
COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
COMPLETED · Phase 3
-
Contrast Enhanced Ultrasound in COVID-19
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.